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FGF7 supports hematopoietic stem and progenitor cells and 
niche-dependent myeloblastoma cells via autocrine action on bone 
marrow stromal cells in vitro 
 
FGF1 and FGF2 support hematopoietic stem and progenitor cells (HSPCs) under stress 
conditions. In this study, we show that fibroblast growth factor (FGF7) may be a novel niche 
factor for HSPC support and leukemic growth. FGF7 expression was attenuated in mouse 
embryonic fibroblasts (MEFs) deficient for the MED1 subunit of the Mediator transcriptional 
coregulator complex. When normal mouse bone marrow (BM) cells were cocultured with 
Med1
+/+
 MEFs or BM stromal cells in the presence of anti-FGF7 antibody, the growth of BM 
cells and the number of long-time culture-initiating cells (LTC-ICs) decreased significantly. 
Anti-FGF7 antibody also attenuated the proliferation and cobblestone formation of MB1 
stromal cell-dependent myeloblastoma cells. The addition of recombinant FGF7 to the coculture 
of BM cells and Med1
−/−
 MEFs increased BM cells and LTC-ICs. FGF7 and its cognate receptor, 
FGFR2IIIb, were undetectable in BM cells, but MEFs and BM stromal cells expressed both. 
FGF7 activated downstream targets of FGFR2IIIb in Med1
+/+
 and Med1
−/−
 MEFs and BM 
stromal cells. Taken together, we propose that FGF7 supports HSPCs and leukemia-initiating 
cells indirectly via FGFR2IIIb expressed on stromal cells. 
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Introduction 
Postnatal mammalian hematopoietic 
stem and progenitor cells (HSPCs) are 
strictly regulated by specific 
microenvironmental niches in the bone 
marrow (BM). BM mesenchymal stem 
cells (MSCs) and their derived or related 
cells constitute important cellular 
components of the hematopoietic niche 
[reviewed in 1-3]. The endosteal region 
of the BM was first identified as the 
resting HSPC reservoir, where osteoblasts 
of mesenchymal origin primarily play a 
niche function. Meanwhile, recent studies 
have highlighted the BM sinusoidal 
vasculature and perivascular region, 
which are composed of MSCs or related 
stromal cells (Nestin
+
 MSCs, CXC 
chemokine ligand 12 
(CXCL12)-abundant reticular cells, 
pericytes, and endothelial cells), as a 
major niche for HSPCs [4-6, reviewed in 
1-3]. Molecular components of the HSPC 
niche include angiopoietin-1 (Ang-1), 
CXCL12, Wnt signaling, and N-cadherin, 
which in concert control HSPC behavior 
[reviewed in 1-3]. We have also reported 
osteopontin (OPN), produced by stromal 
cells, as an important niche factor [7]. 
Fibroblast growth factors (FGFs) 
comprise a large family of 
heparin-binding growth factors that 
regulate cell migration, growth, and 
differentiation/fate. A family of four 
receptor tyrosine kinases, designated FGF 
receptor (FGFR) 1 through FGFR4, acts 
as the specific receptors for FGFs to 
initiate intracellular signaling [reviewed 
in 8,9]. FGFR1 and FGF2 appear to be 
dispensable for homeostatic 
hematopoiesis [10,11]. However, in 
response to stimulatory stresses to HSPCs, 
FGFR1 expressed on HSPCs reportedly 
promotes HSPC expansion through FGF1 
(and possibly FGF4) produced by 
megakaryocytes [10], while FGF2 
produced by megakaryocytes indirectly 
promotes HSPC expansion via the 
proliferation of stromal cells, which in 
turn change the levels of niche signals 
[11]. In this manner, some FGF signaling 
appears to be a key regulator of HSPC 
proliferation and recovery in stressed 
environments. 
FGF7 (also known as keratinocyte 
growth factor), produced by 
mesenchymal cells, binds to and activates 
the specific receptor tyrosine kinase 
FGFR2IIIb, which in turn rapidly 
activates Ras-mitogen-activated protein 
kinase (MAPK) and phosphoinositide 
3-kinase-Akt signaling pathways. 
FGFR2IIIb, expressed mainly on 
epithelial cells, functions in epithelial cell 
growth, wound healing, and hair 
development [reviewed in 8,9]. Upon 
hepatic injury, Thy1
+
 mesenchymal cells 
produce FGF7 in close proximity to liver 
progenitor cells, which subsequently 
proliferate and contribute to liver 
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regeneration. Thus, FGF7 appears to be a 
functional niche signal for the stimulation 
of liver progenitor cells [12]. However, 
the role of FGF7 in HSPC maintenance is 
not known. 
The Mediator transcriptional coregulator 
complex, a subcomplex of RNA 
polymerase II holoenzyme, acts as the 
end-point integrator of a variety of 
activators and conveysintracellular 
signals to the general transcription 
machinery. Among circa 30 subunits, 
MED1 is crucial for various biological 
events through its specific interaction 
with distinct activators, such as nuclear 
receptors [reviewed in 13]. In this study, 
we show that FGF7 expression was 
profoundly attenuated in Med1
−/−
 mouse 
embryonic fibroblasts (MEFs), that FGF7 
produced by MEFs and BM stromal cells 
is a crucial niche factor for HSPC support 
and leukemic growth in vitro, and that 
FGF7 acts indirectly by stimulating 
stromal cells in an autocrine manner. 
 
Materials and methods 
Cell culture 
Stable lines of Med1
+/+
p53
−/−
 and 
Med1
−/−
p53
−/−
 MEFs established from 
embryonic day 10.0 (E10.0) embryos 
derived from a single crossing of 
Med1
+/−
p53
−/−
 mice on a C57BL6 
background were described previously 
[7]. Two lines of these MEFs were 
analyzed in all experiments. The MEFs 
were cultured in Dulbecco’s modified 
Eagle’s medium (DMEM) supplemented 
with 10% fetal bovine serum (FBS) at 
37°C. The OP-9 BM stromal cells, 
distributed by RIKEN BRC through the 
National Bio-Resource of the Ministry of 
Education, Culture, Sports, Science and 
Technology of Japan (MEXT), 
MC-3T3-E1 cells, and MS-5 cells [14] 
were maintained in -modified Eagle’s 
medium (MEM) supplemented with 
20% FBS, 10% FBS, and 20% horse 
serum, respectively. MB-1 stromal 
cell-dependent myeloblastic leukemia 
cells were maintained by coculture with 
mitomycin C-treated OP-9 cells in 
MEM supplemented with 10% FBS, 1× 
non-essential amino acids, and 100 M 
-mercaptoethanol [15,16]. 
 
BM culture and colony-forming cell assay 
MEFs and MS-5 and OP-9 cells (2 × 10
5
), 
treated with 100 g/mL of mitomycin C 
to arrest the cell cycle, were plated on 
0.1% gelatin-coated 12-well plates. The 
next day, 1 × 10
6
 BM cells, harvested 
from the femurs of congenic wild-type 
mice, were added to each well and 
cultured in MyeloCult M5300 (Stem Cell 
Technologies, Canada) and 10 U/mL 
heparin in the absence or presence of 
various amounts of recombinant human 
(rh) FGF7 (R&D Systems), 0.2 g/mL 
anti-mouse (m) FGF7 rabbit polyclonal 
IgG (H-73: sc-7882; Santa Cruz), or 
 - 4 - 
 
normal rabbit IgG (Sigma) at 33°C. 
For long-term culture, half of the medium 
was replaced with fresh medium each 
week. After an 8-week culture period, 
trypsinized cells containing HSPCs 
(adherent and nonadherent) were 
collected and cultured in complete 
methylcellulose medium (MethoCult 
M3434; Stem Cell Technologies) for all 
types of colonies at 37°C for 14 days, and 
the colonies were counted. 
 
DNA synthesis 
Incorporation of bromodeoxyuridine 
(BrdU) into cells cultured in 24-well 
plates, after purging for 6 h, was 
measured by using a cell proliferation 
enzyme-linked immunosorbent assay 
(ELISA) for BrdU (chemiluminescence) 
(Roche). 
 
Quantitation of mRNA 
For quantitative PCR (qPCR), total RNA 
(0.5 g) was used to prepare cDNA with 
the ReverTra Ace qPCR RT Master Mix 
with a gDNA Remover kit (Toyobo). The 
expression of various mouse genes was 
identified by qPCR (StepOnePlus 
Real-Time PCR system; Life 
Technologies). Mouse 
glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) was used as the 
reference marker. The sequences of the 
primers used and the PCR conditions for 
amplification are available upon request. 
 
Western blot analysis 
For western blot analysis, total cell 
lysates were separated by SDS-PAGE, 
blotted onto a nitrocellulose membrane, 
and probed with polyclonal antibodies 
against mFGF7 (above), -actin 
(BioLegend), FGFR substrate 2 (FRS2) 
(H-91: sc-8318; Santa Cruz), 
Phospho-FRS2- (Tyr196) (Cell 
Signaling), mitogen-activated protein 
(MAP) kinase ERK1/ERK2 (Millipore), 
and phospho-MAP kinase ERK1/ERK2 
(Tyr202/204) (Cell Signaling) and with 
monoclonal antibody against 
mFGFR2(IIIb) (133730; R&D Systems). 
Chemiluminescence was detected by an 
ImageQuant LAS 4000mini (GE 
Healthcare). 
 
Statistical analysis 
All assays were performed in triplicate or 
quadruplicate in at least three separate 
experiments. The significance of the 
differences between independent means 
was assessed by Student’s t-test. We 
considered a P value of <0.05 statistically 
s i g n i f i c a n t . 
 
Results 
FGF7 expression is attenuated in 
Med1
−/−
 MEFs 
MEFs, primitive mesenchymal cells 
resembling MSCs, support HSPCs and 
thus mimic the hematopoietic niche [7]. 
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We employed MEFs as an in vitro model 
to analyze the role of MED1 in the BM 
niche and previously reported that the 
ability of Med1
−/− 
MEFs to promote BM 
cell proliferation and support HSPCs is 
reduced relative to that of Med1
+/+
 MEFs 
[7]. Therefore, MED1 in MEFs has a 
crucial role in activating the transcription 
of genes encoding molecules with 
potency for HSPC support. Microarray 
analysis comparing Med1
+/+
p53
−/−
 and 
Med1
−/−
p53
−/−
 MEFs revealed reduced 
expression of Fgf7 and Opn in 
Med1
+/+
p53
−/−
 MEFs (GEO accession 
number GSE22471) [7]. 
 RT-qPCR (Fig. 1A) and western blot 
(Fig. 1B) analyses confirmed the reduced 
level of FGF7 in Med1
−/−
 MEFs. 
However, Fgf7 expression was not 
restored after MED1 was reintroduced 
into Med1
−/−
 MEFs (Rev-Med1
−/−
 MEFs) 
(Fig. 1A), indicating that the reduction in 
Fgf7 expression was an indirect effect of 
Med1 ablation. 
 
FGF7 is expressed in BM mesenchymal 
cells but not in BM hematopoietic cells 
RT-qPCR (Fig. 1A) and western blot 
(Fig. 1B) analyses showed that FGF7 was 
expressed in BM mesenchymal cells, 
including stromal cells (MS-5 and OP-9) 
and osteoblasts (MC3T3-E1), as in 
Med1
+/+
 MEFs, but Fgf7 mRNA was 
undetectable in hematopoietic cells (Fig. 
1A). This implies that the quantity of 
FGF7 secreted by stromal cells reflected 
FGF7 levels in the coculture niche model. 
 
MEF FGF7 mediates mitogenic signal(s) 
to BM cells and the support of long-term 
culture-initiating cells 
We asked whether FGF7 is responsible 
for the phenotypes of Med1
−/−
 MEFs. To 
answer this question, we first analyzed 
the effect of FGF7 on the mitogenicity of 
cocultured BM cells. When BM cells on 
Med1
+/+
 MEFs were cocultured for 2 
weeks in the presence of anti-FGF7 IgG 
or control rabbit whole IgG, the number 
of BM cells in cultures with anti-FGF7 
IgG was lower than in the control 
cultures (Fig. 1C, supplementary Fig. 1A). 
This result, which could be due to a 
specific blocking effect of the antibody, 
prompted us to culture BM cells on 
Med1
−/−
 MEFs in the presence or absence 
of rhFGF7. As expected, the number of 
BM cells increased in an FGF7 
dose-dependent manner (Fig. 1D, 
supplementary Fig. 1B). 
To assess if changes in the cell number 
reflect altered mitogenicity, DNA 
synthesis was measured. After 1 week of 
coculture, the incorporation of BrdU into 
BM cells on Med1
+/+
 MEFs was lower in 
the presence of anti-FGF7 antibody than 
in the control, and the incorporation into 
BM cells on Med1
−/−
 MEFs was higher 
in the presence of rhFGF7 (Fig. 1E). 
Together, these data strongly suggest that 
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FGF7 produced by MEFs had mitogenic 
activity on the cocultured BM cells. 
We then conducted a long-term BM 
culture to assess whether FGF7 affected 
HSPC support. We first cultured BM 
cells on Med1
+/+
 MEFs in the presence of 
anti-FGF7 or control IgG for 8 weeks and 
counted the resulting long-term 
culture-initiating cells (LTC-ICs) by 
colony formation assay. The number of 
LTC-ICs was reduced in the presence of 
anti-FGF7 antibody, probably through its 
blocking effect on FGF7 secreted by 
MEFs (Fig. 1F). BM coculture on 
Med1
−/−
 MEFs in the absence or presence 
of rhFGF7 enhanced the number of 
LTC-ICs in an FGF7 dose-dependent 
manner (Fig. 1F). These data suggested a 
role for FGF7 in HSPC support in a 
MEF-based long-term BM culture. 
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Fig. 1. MEF-produced FGF7 promotes BM cell growth and supports LTC-ICs on MEFs. 
(A and B) Expression of FGF7. Quantitative PCR (A) and western blot analysis (B). FGF7 was expressed in Med1+/+ 
MEFs, BM stromal cells (MS-5 and OP-9), and osteoblasts (MC3T3), and its expression was reduced in Med1−/− 
MEFs (A, B). Fgf7 mRNA expression was not restored in Rev-Med1−/− MEFs and was not detected in BM 
hematopoietic cells (A). (C) The number of BM cells, when cocultured on Med1+/+ MEFs, decreased in the presence 
of anti-FGF7 antibody (Ab). α, anti. (D) The number of BM cells, when cocultured on Med1−/− MEFs, increased in 
the presence of rhFGF7. (E) BM cell DNA synthesis on Med1+/+ MEFs, measured by BrdU incorporation, decreased 
in the presence of anti-FGF7 Ab. BM cell DNA synthesis on Med1+/+ MEFs increased in the presence of rhFGF7. (F) 
Med1+/+ MEFs were reduced in the presence of anti-FGF7 Ab. The number of LTC-ICs on Med1−/− MEFs increased 
in the presence of rhFGF7. The values are the mean ± SD (A, C–E) or mean ± SE (F) of a representative experiment 
performed in triplicate (A) or quadruplicate (C–F) (*, P < 0.05; **, P < 0.01). 
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BM stromal cell FGF7-mediated growth 
of BM cells and LTC-IC support 
Two independently established mouse 
BM stromal cell lines, MS-5 and OP-9, 
represent a BM niche and provide 
long-term HSPC support in vitro [14,17]. 
Therefore, we performed similar 
experiments using these cells. As 
expected, when BM cells were cocultured 
with MS-5 or OP-9 cells for 2 weeks, the 
addition of anti-FGF7 antibody 
attenuated the growth of the cocultured 
BM cells (Fig. 2A and supplementary Fig. 
2A). Similarly, when BM cells were 
cocultured for 8 weeks, the number of 
LTC-ICs was reduced by the addition of 
anti-FGF7 antibody (Fig. 2B and 
supplementary Fig. 2B). These data 
further support the MEF-based 
conclusion that FGF7 has a role in BM 
cell growth and HSPC support in vitro. 
 
BM stromal cell FGF7-mediated growth 
of niche-dependent myeloblastic leukemia 
cells 
MB-1 niche-dependent myeloblastoma 
cells, originally derived from a patient 
with myeloid blast crisis chronic myeloid 
leukemia, require BM stromal cells such 
as OP-9 and MS-5 cells for survival and 
optimal growth. During coculture, 
typically with OP-9 and MS-5 BM 
stromal cells, MB-1 cells form 
cobblestone areas, which most probably 
reconstitute a stochastic model of 
leukemic stem or initiating cells in vitro 
[15,16]. We next asked if FGF7 produced 
by MS-5 or OP-9 BM stromal cells has a 
role in cocultured MB-1 cell growth. 
When anti-FGF7 antibody was added to 
MB-1 cells cocultured with MS-5 or 
OP-9 cells, the proliferation of MB-1 
cells was significantly attenuated, 
although the cells were alive, as judged 
by trypan blue exclusion (Fig. 2C and D). 
Anti-FGF7 antibody also attenuated 
DNA synthesis in MB-1 cells cocultured 
with MS-5 or OP-9 cells (Fig. 2E, 
supplementary Fig. 3A). The number of 
cobblestone areas was also reduced 
significantly when anti-FGF7 antibody 
was added to the coculture, indicating 
reduced stem cell-like features of MB-1 
cells (Fig. 2F, supplementary Fig. 3B). 
These results clearly indicate that BM 
stromal cell FGF7 is important for the 
optimal growth and support of stromal 
cell-dependent myeloblastic leukemia 
cells; it may constitute a leukemic stem 
cell niche. 
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Fig. 2. FGF7 depletion attenuates the growth of BM cells and MB-1 niche-dependent myeloblastoma cells and 
reduces the number of LTC-ICs cocultured on BM stromal cells. 
(A, B) BM cells (A) and LTC-ICs (B) on MS-5 BM stromal cells were counted in the presence of anti-FGF7 Ab. The 
numbers of BM cells and LTC-ICs on stromal cells decreased in the presence of anti-FGF7 Ab. (C, D) The number of 
MB-1 cells on MS-5 (C) or OP-9 (D) BM stromal cells decreased in the presence of anti-FGF7 Ab. (E) BrdU 
incorporation into MB-1 cells cocultured with MS-5 cells was impaired in the presence of anti-FGF7 Ab. The values 
of BrdU incorporation are plotted as the fold increase versus the value with control IgG. (F) The number of 
cobblestone areas per visual field formed by MB-1 cells cocultured with MS-5 cells was counted. The number 
decreased in the presence of anti-FGF7 Ab. The values are the mean ± SD (A, C, D) or SE (B, E, F) of a 
representative experiment performed in quadruplicate (*, P < 0.05; **, P < 0.01). 
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FGF7 receptor FGFR2IIIb is expressed 
on BM mesenchymal cells but not on BM 
hematopoietic cells 
We next investigated the mechanism of 
FGF7 in BM cell growth and HSPC 
support. First, we performed QT-PCR 
analysis to measure the expression of 
FGF receptors on BM hematopoietic cells 
and found that some FGFRs were 
variously expressed. However, 
FGFR2IIIb, the sole and specific receptor 
for FGF7, was completely undetectable 
(Fig. 3A). 
Therefore, FGF7 may act on stromal 
cells in an autocrine manner. Various 
mesenchymal cells were checked for the 
expression of each FGFR. BM 
mesenchymal stromal cells (MS-5 and 
OP-9), osteoblastic cells (MC3T3-E1), 
and MEFs (Med1
+/+
 and Med1
−/−
) 
expressed all of the FGFRs at various 
levels (Fig. 3A). The expression of 
FGFR2IIIb was also examined at the 
protein level by western blot and was 
comparable in all of these cells (Fig. 3B). 
The data suggest that FGF7 might act on 
BM stromal cells in an autocrine (or 
paracrine) manner to elicit niche function 
indirectly by these cells. 
 
FGF7 initiates FGFR-mediated 
intracellular signaling in MEFs and BM 
stromal cells 
Because FGF7 appeared to act on 
stromal cells in the niche model system, 
we asked if treating these cells with 
FGF7 elicited intracellular signaling. To 
this end, we assessed the phosphorylation 
of FRS2 (the immediate target of FGFR 
tyrosine kinase), the phosphorylation of 
MAP kinase (the intermediate hub of 
various intracellular signals), and the 
mRNA levels of immediate early 
response genes [8,9]. 
 In both Med1
+/+
 and Med1
−/−
 MEFs, the 
phosphorylation of FRS2 and MAP 
kinases was upregulated 10 min after the 
addition of 10 or 50 ng/mL FGF7 (Fig. 
4A),  indicating that FGF7 effectively 
elicited FGFR2IIIb tyrosine kinase 
activity with subsequent activation of the 
downstream signaling cascade of 
FGFR2IIIb. We next analyzed the 
response of immediate early gene 
expression. In both Med1
+/+
 and Med1
−/−
 
MEFs, c-Fos, c-Jun, and c-Myc were 
robustly transcribed after the addition of 
10 ng/mL (supplementary Fig. 4) or 50 
ng/mL (Fig. 4B) of FGF7, with a peak 
within 1 hr, followed by attenuation and a 
second wave of transcription (Fig. 4B, 
supplementary Fig. 4). 
Experiments using MS-5 BM stromal 
cells yielded similar results, with prompt 
activation of FRS2 and MAP kinases and 
subsequent transcription of c-Fos and 
c-Myc (supplementary Fig. 5A and B). 
The phosphorylation of FRS2 and MAP 
kinases was also evident after the 
addition of FGF7 to OP-9 cells 
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(supplementary Fig. 5A). Taken together, 
these results clearly show that FGF7 
effectively elicits FGFR2IIIb activation 
and subsequent intracellular signaling in 
MEFs and BM stromal cells and that 
MED1 is dispensable in these systems. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3. Fgfr2IIIb is expressed in MEFs and BM stromal cells, but not in BM hematopoietic cells. 
(A) Quantitative PCR. Fgfr1, 2IIIb, 2c, 3, and 4 mRNAs were expressed in BM stromal cells (MS-5 and OP-9), 
osteoblasts (MC3T3-E1), and MEFs. BM hematopoietic cells expressed Fgfr1, 2c, 3, and 4 mRNAs but not Fgfr2b 
mRNA. The 23 values (mean ± SD of a representative experiment performed in triplicate) are plotted as the fold 
increase versus the value in Med1+/+ MEFs. (B) Western blot. FGF7 receptor FGFR2IIIb was expressed comparably 
in BM stromal cells, osteoblasts, and MEFs.
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Fig. 4. FGF7 initiates FGFR2IIIb-mediated intracellular signaling in both Med1+/+ and Med1−/− MEFs. 
(A) The phosphorylation of FRS2 and MAP kinases was induced 10 min after rhFGF7 addition in MEFs. (B) The 
expression of immediate early genes, c-Fos, c-Jun, and c-Myc, was induced after rhFGF7 addition in MEFs. 
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Discussion 
 We determined the role of FGF7 in a 
hematopoietic niche model. Our findings 
suggest that FGF7 and its cognate 
receptor FGFR2IIIb are specifically 
expressed in mesenchymal stromal cells, 
that FGF7 supports HSPC maintenance, 
and that this activity may be elicited 
indirectly by FGF7-activated stromal 
cells in an autocrine or paracrine manner. 
BM stromal cell FGF7 also constitutes a 
niche for myeloblastic leukemia cells. 
FGF systems have been highlighted in 
recent years as important molecular 
components of microenvironmental 
signals both in hematopoietic (FGF1 and 
FGF2) and liver (FGF7) systems in stress 
conditions. In the liver niche, FGF7 
produced by fibroblastic stroma-like cells 
acts on liver progenitor cells, thus 
constituting a genuine functional niche 
signal [12]. The FGF7-FGFR2IIIb system 
in the hematopoietic niche model and 
liver niche contrasts with the FGF1- and 
FGF2-elicited HSPC expansion in that, 
whereas FGF1 and FGF2 are supplied 
primarily by megakaryocytes, FGF7 is 
produced by stromal cells both in the 
hematopoietic niche (this study) and liver 
niche [12]. In addition, FGF7 acts on 
FGFR2IIIb on mesenchymal stromal 
cells in an autocrine or paracrine manner, 
whereas FGF1 and FGF2 act on cells 
distinct from their origin. 
 The mechanism of niche function by 
FGF7 appears to be essentially indirect: it 
acts not on HSPCs (nor, most likely, on 
leukemic stem cells) but on stromal cells 
themselves, which subsequently act on 
normal and malignant HSPCs by an as 
yet unknown mechanism(s). A precedent 
is the indirect action of FGF7 on thymic 
mesenchymal cells to mediate thymocyte 
proliferation and T cell maturation [18]. 
The thymic mesenchymal cells express 
FGFR2IIIb, and these cells reportedly 
produce bone morphogenic protein 2 
(BMP2), BMP4, Wnt5b, and Wnt10b, 
probably through an indirect mechanism 
downstream of transcription factors such 
as p53 and NF-κB [18]. It will be 
interesting to see if these molecules are 
altered in BM mesenchymal cells as well 
and if they contribute to HSPC support 
a n d  l e u k e m i c  g r o w t h . 
 Although FGF7 is downregulated in 
Med1−/− MEFs, the inability to restore its 
expression by reintroducing FGF7 in the 
cells indicates that the effect of MED1 in 
this process is again indirect; it might 
reflect subtle differences in the 
differentiation status of Med1+/+ MEFs and 
Med1−/− MEFs, reflected in their different 
manner of myogenic differentiation when 
MyoD is added [19]. In Med1−/− MEFs, we 
previously showed that niche molecules, 
including angiopoietin-1, Jagged-1, 
N-cadherin, Wnt, and BMP4, remain 
unchanged [7]. However, the 
transcription of genes encoding the 
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chemokines CXCL1, CXCL5, CXCL10, 
and CXCL15 is significantly reduced in 
Med1−/− MEFs (GEO accession number 
GSE22471) [7]. These chemokines, 
whose functions in the BM 
microenvironment are essentially 
unknown, might contribute to the niche 
function uniquely for HSPC support and 
leukemic cell growth. The action of these 
chemokines on HSPCs in the presence or 
absence of FGF7 must be carefully 
examined in the future. 
 The BM microenvironment is complex 
in terms of cell types, molecules, oxygen 
concentration, and gravity, etc., which 
contribute to HSPC maintenance, 
proliferation, and differentiation. 
Therefore, the effect of niche molecules, 
especially those in families, such as FGFs, 
may not be detected because of 
redundancies within a living animal. 
Thus, a simplified niche model system, 
such as the one adopted in this study, is 
an ideal strategy for assaying molecules 
of interest. However, having established 
FGF7 as a potentially important (both 
normal and malignant) niche factor in 
vitro, the next step is to determine 
whether it has the same role in BM 
mesenchymal stromal cells in vivo. A 
series of mouse knockout models, with 
single or double ablation of genes 
including Fgf7 or Fgfr2IIIb, as well as 
transgenic models, will help answer this 
question in the future. 
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Supplementary Figures 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Fig. 1. FGF7 mediates the growth of BM cells on MEFs. 
The number of BM cells decreased after the addition of anti-FGF7 antibody in cocultures with Med1+/+ MEFs (upper 
panel) and increased after the addition of recombinant human (rh) FGF7 in cocultures with Med1−/− MEFs (lower 
panel). Scale bar, 100 m. 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Fig. 2. FGF7 depletion attenuates the growth of BM cells and the number of LTC-ICs 
cocultured on OP-9 BM stromal cells. (A, B) BM cells (A) and LTC-ICs (B) on OP-9 BM stromal cells were counted 
in the presence of anti-FGF7 Ab. The numbers of BM cells and LTC-ICs on stromal cells decreased in the presence 
of anti-FGF7 Ab. 
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Supplementary Fig. 3. DNA synthesis and cobblestone formation of MB-1 cells cocultured with OP-9 BM 
stromal cells. 
(A) BrdU incorporation into MB-1 cells cocultured with OP-9 cells was impaired in the presence of anti-FGF7 Ab. 
The values of BrdU incorporation are plotted as the fold increase versus the value with control IgG. (B) The number 
of cobblestone areas per visual field formed by MB-1 cells cocultured with OP-9 cells was counted. The number 
decreased in the presence of anti-FGF7 Ab. The values are the mean ±SD of a representative experiment performed 
in quadruplicate (*, P < 0.05; **, P < 0.01). 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Fig. 4. FGF7 initiates FGFR2IIIb-mediated intracellular signaling in MEFs. 
The expression of immediate early genes, c-Fos, c-Jun and c-Myc, was induced after the addition of 10 ng/mL 
rhFGF7 in both Med1+/+ and Med1−/− MEFs. 
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Supplementary Fig. 5. FGF7 initiates FGFR2IIIb-mediated intracellular signaling in BM stromal cells. 
(A) The phosphorylation of FRS2 and MAP kinases was induced 10 min after rhFGF7 addition in OP-9 and MS-5 
BM stromal cells. (B) The expression of immediate early genes, c-Fos and c-Myc, was induced after rhFGF7 addition 
in MS-5 BM stromal cells. 
